3 H]HC-3 in rat cerebral membrane. The percentage of inhibition against the binding of [ 3 H]HC-3 to HAChT were calculated using GraphPad Prism v4 software.
INTRODUCTION
The high-affinity choline uptake system located in peripheral and central cholinergic nerve terminals plays a regulating and rate-limiting role in the
Syntheses and In-vitro Evaluation of Tetrahydroaminoacridine (THA) Based Analogues as High
Affinity Choline Transporter (HAChT) Imaging Probe intraneuronal synthesis of acetylcholine (ACh) (1, 2) . Choline is transferred into the cell by the high-affinity choline transporter where it reacts with acetyl CoA in the presence of the enzyme choline acetyltranferase (ChAT) to form acetylcholine. Brain synaptosome studies demonstrate two carrier-mediated transport systems for choline uptake (3, 4) . At high concentrations, choline is transported primarily by a low-affinity Na + -independent system that is inhibited by hemicholinium-3 (HC-3) (5) with a high K i of approximately 50 μM. This system is thought to be ubiquitously present in cells and to be required for phosphatidylcholine synthesis. At low concentrations choline is transported by a high-affinity, Na + -dependent system that is inhibited by HC-3 with a low K i of 10-100 nM. The high-affinity system is supposed to be present specifically in cholinergic neurons, because a substantial proportion of choline is converted to acetylcholine only when taken up through the high-affinity system (3, 4) . The proposal that the high-affinity choline transport system is unique to cholinergic neurons is supported by the selective loss of the highaffinity choline uptake following depletion of cholinergic terminals in a variety of denervation studies (4) . Choline uptake is generally believed to be the rate-limiting step in acetylcholine synthesis (3, 4) . In addition, the high-affinity choline uptake is regulated by neuronal activity suggesting (6) , that the neuronal 98 activity also regulate acetylcholine synthesis. In Alzheimer's disease, cholinergic neurons selectively degenerate. Consistent with the above hypothesis, the high-affinity choline transporter is reduced in Alzheimer's disease (7) .
Pathogenesis of AD is highly complex. Researchers around the globe have proposed several hypotheses for explaining the mechanism of AD development. Among the hypotheses, cholinergic hypothesis has been widely approved and the most characteristic abnormality associated with AD is the decline of cholinergic neurotransmission. Deficiency in high affinity choline uptake (HACU) by the high affinity choline transporter (HAChT) and the loss of vesicular acetylcholine transporter (VAChT), are two characteristic neurochemical changes in AD. High affinity choline uptake transporter can serve as a useful marker of the functional status of the cholinergic presynaptic terminals and is known to be associated with a variety of diseases, such as Parkinson's disease, Alzheimer's disease, coronary heart diseases, tumor cancers (8, 9) . Thus, choline transporter systems provide attractive targets for the development of PET biomarkers to probe brain, heart, and cancer diseases.
Tacrine (9-amino-1,2,3,4-tetrahydroacrydine, THA, commercial name: Cognix), is a well known acetylcholinesterase (AChE) inhibitor, which produces clinically significant improvement in some cognitive deficits observed in AD patients by increasing the synaptic availability of Ach by inhibiting the AChEmediated degradation of ACh to choline and acetate. But efficacies of this drug are limited and commonly associated with gastrointestinal side effects during long treatment period (10) . Besides this, there is a deficiency of choline uptake in AD patients. Hence, activation of the presynaptic cholinergic function by improving the reduced HACU is another better approach for the treatment of AD.
Although, THA has no effect as HACU enhancer, THA contained 4-aminopyridine (4 -AP) as a partial structure, which is already known to increase HACU and 1-nitrogen atom of 4-AP, also corresponds to the quaternary amine of ACh( Figure 1 ).In 1995, Chaki, H., et al showed acylation of THA leads to the synthesis of novel choline uptake enhancers which improve the reduced HACU and also that some of the structural features of N-acyl derivatives of THA resembles acetylcholine. But due to this structural modification THA lose its activity as AChE inhibitors (11) .
Taking into the consideration, this special characteristic feature of N-acyl derivatives of THA as HACU enhancer and the role of HAChT to enhance HACU, we have synthesized tacrine, the 2,3-dimethylfuran derivative of tacrine (DMTA) and their corresponding 2-oxo-1-pyrrolidineacetyl derivatives, namely PTAA and MKC-231 and evaluated these compounds through in vitro 
MATERIALS AND METHODS Chemical Syntheses:
The syntheses of Tacrine, the 2,3-dimethylfuran derivative of Tacrine (DMTA) and their corresponding 2-oxo-1-pyrrolidineacetyl derivatives, namely PTAA and MKC-231, were accomplished with the following schemes: 
Preparation of rat cerebral and liver membranes
Animal experiments were performed in compliance with the guidelines for the care and use of Laboratory Animals at the Takara-machi Campus of Kanazawa University. Brain homogenate of rats were prepared with the slight modification of previously described protocol (12) . Sprague-Dawley rats (8 weeks, male, 250-300 g) cerebrum or liver were homogenized in ice-cold 0.32 M sucrose with a Teflon-glass homogenizer. The homogenate was centrifuged at 1000g at C for 30 min. The incubation was terminated by putting tubes into ice-cold water followed by immediate filtration using a cell harvester through glassmicrofiber filters (Whatman, GF/B), which were presoaked in 0.5% (v/v) polyethyleneimine for one hour to reduce non-specific binding. The filters were washed with 50 mM Tris-HCl buffer (pH=7.8), and the radioactivity was counted with the liquid scintillation counter (Aloka, LSC-5100).
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RESULTS
Chemistry:
The cyclization of 2-Amino benzonitrile (1) and 2-Amino-4, 5-dimethyl-3-furancarbonitrile (2) with cyclohexanone by means of ZnCl 2 in toluene, furnished tacrine (3) and DMTA (4), respectively (21)( Figure 5 ). The acylation of Tacrine (3) and DMTA (4) with methyl 2-oxo-1-pyrrolidineacetate furnished PTAA (5) and MKC-231 (6) with the yield of 79% and 65% respectively ( Figure 6 ). 
DISCUSSIONS
High affinity choline uptake (HACU) system is located especially in presynaptic cholinergic nerve terminals. HACU by the HAChT is found to be a regulating and rate-limiting step in the synthesis of ACh. Hence, a ligand with a high affinity for HAChT would be an ideal marker for the study of the state of cholinergic presynaptic terminals.Hemicholinium-3 is an indirect acetylcholine antagonist, because it decreases the synthesis of acetylcholine by inhibiting the reuptake of choline by the high-affinity choline transporter (ChT). As HC-3 is a quaternary ammonium salt (Figure 8 ), it cannot cross BBB and radiolabeled quaternary ammonium HC-3 derivatives cannot be used for in vivo visualization of the HACU transporter. MKC-231, 2-(2-Oxo-pyrrolidine-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro [2, 3-b] quinolin-4-yl) acetoamide, has been reported to enhance HACU in hippocampal synaptosomes in in vitro treatment and ameliorates learning deficits in AF64A-treated rats with a single oral administration (22). Although MKC-231 potentially enhances cholinergic activity at synaptic terminals and improves learning impairment observed in AF64A-treated rats and mice, no precise HACU
